Evidence map›Paper›PMID 26150590›Full record

ArticleJournal of the National Cancer Institute2015

M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.

Alexandre de la Fuente, Lorena Alonso-Alconada, Clotilde Costa, Juan Cueva, Tomas Garcia-Caballero, Rafael Lopez-Lopez, Miguel Abal

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alexandre de la FuenteTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Lorena Alonso-AlconadaTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Clotilde CostaTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Juan CuevaTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Tomas Garcia-CaballeroTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Rafael Lopez-LopezTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC).
Miguel AbalTranslational Medical Oncology, Health Research Institute of Santiago, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (AdlF, LAA, CC, JC, RLL, MA); Department of Morphological Sciences, Faculty of Medicine-USC, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain (TGC). miguel.abal.posada@sergas.es.
Universidade de Santiago de Compostela · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRemodeling targeted tissues for reception of tumor cells metastasizing from primary lesions is a consequence of communication between the tumor and the environment that governs metastasis. This study describes a novel approach that aims to disrupt the process of metastasis by interfering with this intense dialogue.

methodsProteomics and adhesion assays identified exosomes purified from the ascitic fluid of ovarian cancer patients (n = 9) as intermediaries of tumor cell attachment. A novel tumor cell capture device was fabricated by embedding exosomes onto a 3D scaffold (metastatic trap [M-Trap]). Murine models of ovarian metastasis (n = 3 to 34 mice per group) were used to demonstrate the efficacy of M-Trap to capture metastatic cells disseminating in the peritoneal cavity. Kaplan-Meier survival curves were used to estimate cumulative survival probabilities. All statistical tests were two-sided.

resultsThe exosome-based M-Trap device promoted tumor cell adhesion with a nonpharmacological mode of action. M-Trap served as a preferential site for metastasis formation and completely remodeled the pattern of peritoneal metastasis in clinically relevant models of ovarian cancer. Most importantly, M-Trap demonstrated a statistically significant benefit in survival outcomes, with mean survival increasing from 117.5 to 198.8 days in the presence of M-Trap; removal of the device upon tumor cell capture further improved survival to a mean of 309.4 days (P < .001).

conclusionsA potent artificial premetastatic niche based on exosomes is an effective approach to impair the crosstalk between metastatic cells and their environment. In the clinical setting, the capacity to modulate the pattern of dissemination represents an opportunity to control the process of metastasis. In summary, M-Trap transforms a systemic, fatal disease into a focalized disease where proven therapeutic approaches such as surgery can extend survival.

Indexed as

ExosomesAnimalsAscitic FluidCell AdhesionCell Line, TumorFemaleHumansKaplan-Meier EstimateMiceNeoplasms, ExperimentalOvarian NeoplasmsPeritoneal Neoplasms

Identifiers

PMID26150590
PMCPMC4836824
OpenAlexW1840744886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.